Prognostic factors of male breast cancer: A monocentric experience.

Breast disease Pub Date : 2023-01-01 DOI:10.3233/BD-220073

Wala Ben Kridis, Mayssa Lajnef, Faida Bouattour, Nabil Toumi, Jamel Daoud, Afef Khanfir

{"title":"Prognostic factors of male breast cancer: A monocentric experience.","authors":"Wala Ben Kridis, Mayssa Lajnef, Faida Bouattour, Nabil Toumi, Jamel Daoud, Afef Khanfir","doi":"10.3233/BD-220073","DOIUrl":null,"url":null,"abstract":"Background: Male breast cancer (MBC) is a rare malignancy presenting only 1% of all breast cancer. The purpose of this study was to analyze clinical and pathological prognostic factors of MBC.Methods: This is a retrospective study including 32 men diagnosed and treated for a primary breast cancer at the department of medical oncology in Sfax between 2005 and 2020.Results: The incidence of MBC was 1.3%. The median age of our patients was 55 years (range: 29-85 years). The average tumor size of 3.9 cm. Lymph nodes involvement was present in 18 cases (56.2%) with capsular rupture in 52% cases. Tumor was grade II in 71.8 % of cases. The expression of hormonal receptors was founded in 100% of cases. Two patients had an overexpression of HER2 (6.2%). There was no case of triple negative MBC. The OS at 5 and 10 years was 67.8% and 30.8% respectively. Prognostic factors were T4 (p = 0.015), involved nodes (p = 0.035), M+ (p = 0.01), SBR III (p = 0.0001) and HER2+++ (p = 0.001).Conclusion: Contrary to breast cancer in women, our study showed that Tunisian MBC have positive hormone receptors in all cases. Although the overexpression of HER2 was low (8.33%) and there was no case of triple negative MBC, the prognosis was poor because of T4 stage, involved nodes, SBR III and distant metastases.","PeriodicalId":9224,"journal":{"name":"Breast disease","volume":"42 1","pages":"271-275"},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast disease","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/BD-220073","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Male breast cancer (MBC) is a rare malignancy presenting only 1% of all breast cancer. The purpose of this study was to analyze clinical and pathological prognostic factors of MBC.

Methods: This is a retrospective study including 32 men diagnosed and treated for a primary breast cancer at the department of medical oncology in Sfax between 2005 and 2020.

Results: The incidence of MBC was 1.3%. The median age of our patients was 55 years (range: 29-85 years). The average tumor size of 3.9 cm. Lymph nodes involvement was present in 18 cases (56.2%) with capsular rupture in 52% cases. Tumor was grade II in 71.8 % of cases. The expression of hormonal receptors was founded in 100% of cases. Two patients had an overexpression of HER2 (6.2%). There was no case of triple negative MBC. The OS at 5 and 10 years was 67.8% and 30.8% respectively. Prognostic factors were T4 (p = 0.015), involved nodes (p = 0.035), M+ (p = 0.01), SBR III (p = 0.0001) and HER2+++ (p = 0.001).

Conclusion: Contrary to breast cancer in women, our study showed that Tunisian MBC have positive hormone receptors in all cases. Although the overexpression of HER2 was low (8.33%) and there was no case of triple negative MBC, the prognosis was poor because of T4 stage, involved nodes, SBR III and distant metastases.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

男性乳腺癌的预后因素:单中心经验。

背景:男性乳腺癌(MBC)是一种罕见的恶性肿瘤，仅占所有乳腺癌的1%。本研究的目的是分析MBC的临床和病理预后因素。方法:这是一项回顾性研究，包括2005年至2020年间在Sfax内科肿瘤科诊断和治疗的32名原发性乳腺癌患者。结果:MBC发病率为1.3%。患者的中位年龄为55岁(范围:29-85岁)。肿瘤平均大小3.9 cm。淋巴结受累18例(56.2%)，包膜破裂52%。71.8%的病例肿瘤为II级。激素受体的表达在100%的病例中被发现。2例患者HER2过表达(6.2%)。无三阴性MBC病例。5年和10年生存率分别为67.8%和30.8%。预后因素为T4 (p = 0.015)、受累淋巴结(p = 0.035)、M+ (p = 0.01)、SBR III (p = 0.0001)、HER2++ (p = 0.001)。结论:与女性乳腺癌相反，我们的研究表明突尼斯MBC在所有病例中都有阳性激素受体。虽然HER2过表达率较低(8.33%)，且无三阴性MBC病例，但由于存在T4期、累及淋巴结、SBR III型及远处转移，预后较差。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Breast disease Medicine-Oncology

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The recent expansion of work in the field of breast cancer inevitably will hasten discoveries that will have impact on patient outcome. The breadth of this research that spans basic science, clinical medicine, epidemiology, and public policy poses difficulties for investigators. Not only is it necessary to be facile in comprehending ideas from many disciplines, but also important to understand the public implications of these discoveries. Breast Disease publishes review issues devoted to an in-depth analysis of the scientific and public implications of recent research on a specific problem in breast cancer. Thus, the reviews will not only discuss recent discoveries but will also reflect on their impact in breast cancer research or clinical management.